FDA Approves Melanoma Cancer Drug from OHC Clinical Trial Participation
OHC participated in the clinical trial titled, “A Single-Arm, Open-Label, Expanded Access Study of RO5185426 in Patients with Metastatic Melanoma.” The purpose of this clinical trial was to allow access to this study drug to patients in which there was no other treatment available.
This study drug was thought to block the multiplication and spread of cancer cells in patients with malignant melanoma. This clinical trial studied the patient response to this study drug and the safety of this study drug.
The study drug used in this trial was approved for prescription use by the Food and Drug Administration in 2011. Zelboraf (vemurafenib) is a prescription medicine used to treat a type of skin cancer called melanoma that has spread to other parts of the body or cannot be removed by surgery.
For more information, visit Zelboraf.